While the available clinical data for GIPR-modulating drugs have been recently compiled [6], a variety of factors impacting the clinical development of GIPR antagonists for the treatment of obesity deserve consideration, including the choice of modality for the active pharmaceutical ingredient (API), dose size, and potential inhibition of beneficial physiological effects of GIP. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.